Overview

Assessment of GVG for the Treatment of Methamphetamine Dependence

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if GVG can reduce drug use and determine safety and effects of GVG when used together with methamphetamine. This study involves staying in the hospital for 21 days. Participants will receive either placebo or GVG, and a limited amount if methamphetamine will be injected on some study days. This study will enroll people that use methamphetamine. Participants will be compensated.
Phase:
Phase 1
Details
Lead Sponsor:
Baylor College of Medicine
National Institute on Drug Abuse (NIDA)
Collaborator:
University of California, Los Angeles
Treatments:
Methamphetamine
Vigabatrin